BS
Brian Taylor Slingsby (Director) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in Mineralys Therapeutics, Inc. (MLYS). The largest single filing was $43.4M of MLYS (1,000,000 sh × $43.35, as filed), executed Nov 20 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
2
0 buys · 2 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$3.0M
shares × price, as filed
Last traded
Sep 22
Filed Sep 24
Median ADV $38.0M across their filed names
Open performance→Volume by month
Buys $3.5M
Sells $46.4M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
MLYS
Mineralys Therapeutics, Inc.
MLYS · 1 buy · 2 sells
3 filings
Recent filings
MLYSSALE
Mineralys Therapeutics, Inc.
View filing →
$3.0M104,320 sh × $28.81
Exec Sep 22
Filed Sep 24 · 9:49 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $43.4M
1,000,000 sh × $43.35
Exec Nov 20 2025
Filed Nov 21 2025 · 5:30 PM ET MLYSPURCHASE Mineralys Therapeutics, Inc. View filing → $3.5M
259,259 sh × $13.50
Exec Mar 13 2025
Filed Apr 25 2025 · 5:30 PM ET †